Trial Trends™ is a podcast brought to you by 4G Clinical, co-hosted by Kathleen Greenough and Elizabeth (Libbi) Rickenbacher. Trial Trends™ tells stories that are often left untold: tackling big ideas, challenging the status quo and bringing perspectives to light on the rapidly changing world of clinical trials.
How expectations at the start of the year evolved under real world pressure, from AI ambition to geopolitical complexity, and what that means for trial operations going forward.
A milestone moment, reflecting on 4G Clinical’s journey to 1000 studies, celebrating partnerships and progress, and setting the stage for what’s next.
A behind-the-scenes look at what it takes to deliver quality at scale—people, processes, and lessons learned from 1000 studies.
The evolution of clinical trials has not been synonymous with the word simple. In the modern world of life sciences, clinical trials have hugely evolved and continue to rise and complexity, whether it's the IMP and treatments themselves, the way they are administered supply management algorithms or the actual protocol designs... the list goes on. Throughout the years, this rising complexity has been matched with advancements in technology to help quell its takeover.
In today's episode, we will explore the evolution of randomization technologies and how modern RTSM systems have developed to help address the high degree of complexity found in today's clinical trials.
Blockchain has been a buzzword in the pharmaceutical industry for awhile now: at industry conferences and in the press. Other industries, like retail, have already implemented early forms of this technology within the larger scope of their processes. But when it comes to our industry, there's still an air of skepticism. This podcast explores the implications of blockchain technology within the pharmaceutical industry as a whole.
In the life sciences industry, we’ve seen regulators play a critical role in helping to pave the way for increased creativity in clinical trial designs. Yet, there are still questions on whether innovation and quality can truly coexist in clinical trials. This episode aims to tackle the "why" behind quality because the answer to this key question brings light to this important issue as clinical trial complexity continues to rise.
For a variety of reasons, some patients in clinical trials hit a "brick wall" in terms of treatment options. This often leads to a feeling of helplessness when trying to understand what the next steps might be. In this episode, Libbi Rickenbacher is joined by Brad Power, Founder of CancerHacker Lab to discuss what can be done to promote patient advocacy within individual patient experiences, and within the larger clinical trial landscape.
Listen in as 4G Clinical's Elana Rose shares her own story living with an invisible illness on this podcast episode. Not just to inspire those currently diagnosed with brain tumors but also to help spread awareness on rare diseases across the globe and bring greater hope to patients around the world.
In part 2 of this episode, Azadeh Nolan gives us a peek behind the curtain on what it's like to plan, develop and execute clinical trials within the pharmaceutical industry.
Since the onset of the COVID-19 pandemic, the pharmaceutical industry has been under intense scrutiny, and social media is driving much of its public perception in today's environment. In part 1 of this episode, Azadeh Nolan, tells her personal experience on working within the industry during COVID and being a source of information for her closest friends, family and even the general public at large.